Sign In
Buy VERX
$12.98
+0.600 (+4.85%)
At Close: Jul 13, 2026
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
02:27pm, Monday, 13'th Jul 2026
Vertex is buying Crinetics Pharmaceuticals for $10 billion. The acquisition could add up to $5 billion in revenue.
Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse
05:03pm, Saturday, 11'th Jul 2026
Vertex Pharmaceuticals NASDAQ: VRTX said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transaction Vertex executives described as a strat
Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?
04:05am, Friday, 10'th Jul 2026
Vertex Pharmaceuticals is the global leader in cystic fibrosis treatments, and this has translated into billion-dollar earnings. The biotech has taken key steps in recent years to expand into other tr
Nvidia, Vertex Pharmaceuticals And More On CNBC's ‘Final Trades'
07:45am, Thursday, 09'th Jul 2026
On CNBC's “Halftime Report Final Trades,” Bryn Talkington, managing partner of Requisite Capital Management, named Roundhill Memory ETF (NASDAQ:DRAM) as her final trade.
Vertex's Crinetics Deal Balances Growth with Integration Risk
09:05am, Wednesday, 08'th Jul 2026
Vertex Pharmaceuticals NASDAQ: VRTX recently announced its plans to acquire Crinetics Pharmaceuticals NASDAQ: CRNX for $10 billion. The deal, which has already been approved by the board of dir
Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It.
03:28am, Wednesday, 08'th Jul 2026
Crinetics' Palsonify was FDA-approved late last year. The company's atumelnant is currently in late Phase 3 clinical testing.
Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know.
11:00pm, Tuesday, 07'th Jul 2026
Vertex agreed to buy Crinetics for $85 per share in cash, about $10 billion in equity value. The deal adds a newly launched acromegaly drug and a late-stage candidate with more than $5 billion in comb
Vertex to Announce Second Quarter 2026 Financial Results on August 3rd
04:00pm, Tuesday, 07'th Jul 2026
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2026 financial results on Monday, August 3, 2026, after the financial markets close. The comp
Crinetics shares surge after Vertex agrees to $10B cash buyout
09:38am, Tuesday, 07'th Jul 2026
Crinetics Pharmaceuticals shares surged after Vertex Pharmaceuticals announced an agreement to acquire the endocrinology-focused biotech company in a deal valued at approximately $10 billion. The all-
Vertex Sees Over $5 Billion Peak Sales Potential From Crinetics Assets
08:24am, Tuesday, 07'th Jul 2026
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday agreed to acquire Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) for $85 per share in cash, a total equity value of approximately $10 billion
Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion
05:02pm, Monday, 06'th Jul 2026
The acquisition would add to Vertex's pipeline and potentially grow its annual revenue by $5 billion with the addition of Crinetics-developed drugs Palsonify and Atumelnant, the company said.
Vertex Pharma Makes A $10 Billion Deal; Biotech Stock Doubles
04:49pm, Monday, 06'th Jul 2026
Crinetics stock nearly doubled late Monday after Vertex Pharmaceuticals pledged $10 billion to buy the endocrinology-focused biotech company.
Vertex to buy Crinetics in $10 billion deal
04:10pm, Monday, 06'th Jul 2026
Vertex Pharmaceuticals will buy Crinetics Pharmaceuticals for a total equity value of about $10 billion, the companies said on Monday.
Vertex to Acquire Crinetics Pharmaceuticals
04:04pm, Monday, 06'th Jul 2026
BOSTON & SAN DIEGO--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, de
Vertex Pharmaceuticals Stock Is Soaring and at a New All-Time High. Could It Still Be Heading Even Higher?
03:10pm, Monday, 06'th Jul 2026
Vertex's business is growing modestly but there's much more growth potentially on the horizon. The stock's valuation has risen significantly and it's trading far higher than the S&P 500 average.
